<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d502">
    <sentence id="DDI-DrugBank.d502.s0" text="Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.">
        <entity id="DDI-DrugBank.d502.s0.e0" charOffset="0-7"
            type="brand" text="Ocupress"/>
        <entity id="DDI-DrugBank.d502.s0.e1" charOffset="69-98"
            type="group" text="beta-adrenergic blocking agent"/>
        <ddi id="DDI-DrugBank.d502.s0.d0" e1="DDI-DrugBank.d502.s0.e0"
            e2="DDI-DrugBank.d502.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d502.s1" text="Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.">
        <entity id="DDI-DrugBank.d502.s1.e0" charOffset="55-66"
            type="group" text="beta-blocker"/>
        <entity id="DDI-DrugBank.d502.s1.e1" charOffset="144-152"
            type="drug" text="reserpine"/>
        <ddi id="DDI-DrugBank.d502.s1.d0" e1="DDI-DrugBank.d502.s1.e0"
            e2="DDI-DrugBank.d502.s1.e1" type="advise"/>
    </sentence>
</document>
